Compare Quest Diagnostics Inc (DGX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Johnson Controls International PLC — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Johnson Controls International PLC trades at $157.44 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 3.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Johnson Controls International PLC for 65 Days on average.
| DGX | JCI | |
|---|---|---|
Market Cap | $25.48B | $93.28B |
Volume | 941,866 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $158.76 |
52-Week Low | $173.49 | $105.55 |
Typical Hold Time | 56 Days | 65 Days |
Enterprise Value | $31.23B | $102.12B |
Dividend Yield | 1.49% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Johnson Controls International (JCI) trades at $154.00, down 1.24% on the day, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results showing 10% organic sales growth and a raised full-year outlook. Valuation ratios are elevated, but profitability metrics like a 14.32% net income margin and 24.42% ROE reflect solid fundamental strength.
The outlook for JCI is positive, driven by robust demand for its building systems and data center thermal management solutions. Key opportunities include continued execution on record backlog and AI-driven industrial stock tailwinds. Risks involve high debt levels and sensitivity to economic cycles. With a consensus price target of $172.50 implying ~12% upside, Wall Street sentiment remains bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
